Using a pessary during radiotherapy in reducible pelvic organ prolapse and vaginal cancer: a case report and review of the literature.
brachytherapy
pelvic organ prolapse
pessary
primary vaginal cancer
radiotherapy
Journal
Journal of contemporary brachytherapy
ISSN: 1689-832X
Titre abrégé: J Contemp Brachytherapy
Pays: Poland
ID NLM: 101506276
Informations de publication
Date de publication:
Apr 2020
Apr 2020
Historique:
received:
04
09
2019
accepted:
15
12
2019
entrez:
13
5
2020
pubmed:
13
5
2020
medline:
13
5
2020
Statut:
ppublish
Résumé
Primary vaginal cancer and pelvic organ prolapse (POP) combination is extremely rare. Although definitive chemoradiotherapy (CRT) and brachytherapy (BT) is the standard treatment for advanced stage primary vaginal cancer, there is a limited data about the treatment of primary vaginal cancer combined with POP due to its rarity. In addition, radiotherapy (RT) process may be difficult in these cases and often result in more toxicity. In this case report, we present a 77-year-old woman with a diagnosis of primary vaginal cancer associated with POP, who was treated with definitive CRT using a pessary to restore vaginal anatomy for optimal radiation. Following CRT, complete response was observed and vaginal cuff BT was performed. The patient tolerated the treatment very well and is still alive without disease at 10-months follow-up. Combined primary vaginal cancer and POP is an extremely rare clinical entity, with only a few cases reported in the literature. When applying CRT in these cases, critical organ doses may be higher than expected due to the downward descent of the pelvic organs. Especially in elderly patients, a pessary can be used as a non-surgical procedure to restore the anatomy for symptom relief during definitive CRT. Additionally, it allows tumors to be targeted more precisely.
Identifiants
pubmed: 32395142
doi: 10.5114/jcb.2020.92997
pii: 39879
pmc: PMC7207234
doi:
Types de publication
Case Reports
Langues
eng
Pagination
175-180Informations de copyright
Copyright © 2020 Termedia.
Déclaration de conflit d'intérêts
The authors report no conflict of intertest.
Références
Eur J Gynaecol Oncol. 2006;27(5):528-30
pubmed: 17139994
J Menopausal Med. 2013 Dec;19(3):139-42
pubmed: 25371880
Int J Surg. 2006;4(4):242-50
pubmed: 17462358
Obstet Gynecol. 2014 Jan;123(1):141-8
pubmed: 24463674
Gynecol Oncol Rep. 2018 Aug 16;26:14-16
pubmed: 30148199
Arch Gynecol Obstet. 2007 Jun;275(6):503-5
pubmed: 17123094
Arch Gynecol Obstet. 2009 Nov;280(5):845-8
pubmed: 19263061
J Med Life. 2011 Jan-Mar;4(1):75-81
pubmed: 21505577
Medicine (Baltimore). 2017 Dec;96(50):e8993
pubmed: 29390294
Gynecol Oncol. 2007 Jun;105(3):641-9
pubmed: 17363046
BMC Womens Health. 2019 May 23;19(1):69
pubmed: 31122220
Aust N Z J Obstet Gynaecol. 1995 Nov;35(4):463-4
pubmed: 8717582
Eur J Obstet Gynecol Reprod Biol. 2011 Jun;156(2):125-30
pubmed: 21255901
J Indian Med Assoc. 1989 Jan;87(1):10-2
pubmed: 2754264
Gynecol Obstet Invest. 2014;77(2):141-4
pubmed: 24481208
Arch Gynecol Obstet. 2009 Jan;279(1):91-3
pubmed: 18936946
Int J Cancer. 2009 Apr 1;124(7):1626-36
pubmed: 19115209
J Natl Cancer Inst Monogr. 2003;(31):14-9
pubmed: 12807940
Int J Gynaecol Obstet. 2009 Apr;105(1):3-4
pubmed: 19322933
Br J Radiol. 1985 Jun;58(690):515-28
pubmed: 4063711
Int J Radiat Oncol Biol Phys. 2005 May 1;62(1):138-47
pubmed: 15850914
Eur J Gynaecol Oncol. 2008;29(3):272-5
pubmed: 18592794
Postgrad Med J. 1984 Jun;60(704):435-6
pubmed: 6462989
Arch Gynecol Obstet. 2007 Nov;276(5):563-4
pubmed: 17628814
Int Urogynecol J. 2011 Nov;22(11):1459-61
pubmed: 21562914
Acta Obstet Gynecol Scand. 1957;36(2):257-61
pubmed: 13434883
CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30
pubmed: 26742998
Lancet. 2007 Mar 24;369(9566):1027-38
pubmed: 17382829
Am J Obstet Gynecol. 1991 Oct;165(4 Pt 2):1255-62
pubmed: 1659200